Scribe Therapeutics (SCTX) catalysts

Upcoming FDA decisions and readouts we track for Scribe Therapeutics, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 12 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Scribe Therapeutics (SCTX, listed on Nasdaq). It concerns STX-1150 (Elevated LDL-C and ASCVD risk (in vivo CRISPR)).

First on the list: the Phase 1 readout for STX-1150 (Elevated LDL-C and ASCVD risk (in vivo CRISPR)), guided by the company to H1 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: SCTX
Next catalyst: H1 2027
Type: Phase 1 readout
Listed options: No

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Scribe Therapeutics SCTX · Nasdaq	STX-1150	Elevated LDL-C and ASCVD risk (in vivo CRISPR)	H1 2027 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	No
Notes — Filing states Scribe "anticipates reporting initial clinical data, including safety, tolerability, and LDL-C lowering activity, from the single ascending dose (SAD) portion of the STX-1150 Phase 1 trial in the first half of 2027." Source: 8-K exhibit 99.1, filed 02 Sep 2026 · verified 12 Sep 2026

Companies working on related conditions

Monte Rosa Therapeutics (GLUE)Elevated cardiovascular disease risk (NEK7 degrader); Advanced castration-resistant prostate cancer
Sana Biotechnology (SANA)Non-Hodgkin lymphoma (in vivo CAR-T)
Tempest Therapeutics (TPST)Myasthenia gravis / multiple sclerosis (CD7 in vivo CAR-T)